Leanne de Koning

3.8k total citations
66 papers, 2.3k citations indexed

About

Leanne de Koning is a scholar working on Molecular Biology, Oncology and Ophthalmology. According to data from OpenAlex, Leanne de Koning has authored 66 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 20 papers in Oncology and 12 papers in Ophthalmology. Recurrent topics in Leanne de Koning's work include Ocular Oncology and Treatments (12 papers), Ubiquitin and proteasome pathways (7 papers) and Immunotherapy and Immune Responses (6 papers). Leanne de Koning is often cited by papers focused on Ocular Oncology and Treatments (12 papers), Ubiquitin and proteasome pathways (7 papers) and Immunotherapy and Immune Responses (6 papers). Leanne de Koning collaborates with scholars based in France, United States and Netherlands. Leanne de Koning's co-authors include Geneviève Almouzni, Armelle Corpet, James E. Haber, Thierry Dubois, Brigitte Picard, Muriel Bonnet, Mohammed Gagaoua, Xavier Sastre‐Garau, Alexia Savignoni and Bernard Asselain and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Leanne de Koning

65 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leanne de Koning France	27	1.5k	486	445	379	257	66	2.3k
Carlos Becerra United States	24	1.4k 0.9×	1.1k 2.2×	379 0.9×	398 1.1×	101 0.4×	98	2.5k
Eisaku Yoshida Japan	16	1.3k 0.9×	517 1.1×	149 0.3×	105 0.3×	180 0.7×	36	1.8k
Jingyi Yu China	11	1.2k 0.8×	330 0.7×	342 0.8×	107 0.3×	148 0.6×	22	1.8k
Guocan Wang United States	20	1.6k 1.1×	862 1.8×	641 1.4×	542 1.4×	207 0.8×	33	2.6k
Gloria Juan United States	22	1.3k 0.9×	759 1.6×	344 0.8×	111 0.3×	434 1.7×	50	2.1k
Paola Parrella Italy	29	2.3k 1.5×	773 1.6×	1.1k 2.4×	363 1.0×	137 0.5×	79	3.3k
Stéphane Gobeil Canada	19	1.1k 0.7×	246 0.5×	349 0.8×	92 0.2×	146 0.6×	33	1.6k
Constanze Wiek Germany	26	1.0k 0.7×	512 1.1×	244 0.5×	96 0.3×	103 0.4×	62	1.7k
Andrew C. Phillips United States	18	2.1k 1.3×	1.7k 3.6×	378 0.8×	130 0.3×	270 1.1×	29	2.7k

Countries citing papers authored by Leanne de Koning

Since Specialization

Citations

This map shows the geographic impact of Leanne de Koning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne de Koning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne de Koning more than expected).

Fields of papers citing papers by Leanne de Koning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne de Koning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne de Koning. The network helps show where Leanne de Koning may publish in the future.

Co-authorship network of co-authors of Leanne de Koning

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne de Koning. A scholar is included among the top collaborators of Leanne de Koning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne de Koning. Leanne de Koning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kooij, Monique K. van der, Ellen Kapiteijn, Piotr Rutkowski, et al.. (2025). Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres. European Journal of Cancer. 227. 115634–115634. 1 indexed citations

Mariani, Pascale, Steven Van Laere, Peter Vermeulen, et al.. (2023). Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases. British Journal of Cancer. 129(5). 772–781. 8 indexed citations

Rodrigues, Manuel, Toulsie Ramtohul, Leanne de Koning, et al.. (2023). PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.. Journal of Clinical Oncology. 41(16_suppl). TPS9613–TPS9613. 1 indexed citations

Koning, Leanne de, Vincent Servois, Toulsie Ramtohul, et al.. (2022). Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients. OncoImmunology. 11(1). 2116845–2116845. 11 indexed citations

Brédart, Anne, É. Seigneur, Leanne de Koning, et al.. (2021). Helping Patients Communicate With Oncologists When Cancer Treatment Resistance Occurs to Develop, Test, and Implement a Patient Communication Aid: Sequential Collaborative Mixed Methods Study. JMIR Research Protocols. 11(1). e26414–e26414. 2 indexed citations

Piperno‐Neumann, Sophie, James Larkin, Richard D. Carvajal, et al.. (2020). Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Molecular Cancer Therapeutics. 19(4). 1031–1039. 41 indexed citations

Gérossier, Laetitia, A. Dubois, Nadim Farés, et al.. (2020). PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles’ heel?. Clinics and Research in Hepatology and Gastroenterology. 45(5). 101553–101553. 12 indexed citations

Caruso, Stefano, Tiziana La Bella, Sandrine Imbeaud, et al.. (2019). Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology. 157(3). 760–776. 133 indexed citations

Tranchant, Robin, Lisa Quetel, François Montagne, et al.. (2018). Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma. Lung Cancer. 126. 15–24. 10 indexed citations

10.

Rebouissou, Sandra, Tiziana La Bella, Sandrine Imbeaud, et al.. (2017). Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro. Clinical Cancer Research. 23(15). 4364–4375. 48 indexed citations

11.

Neuzillet, Y., Elodie Chapeaublanc, Clémentine Krucker, et al.. (2017). IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer. BMC Cancer. 17(1). 636–636. 19 indexed citations

12.

Tranchant, Robin, Lisa Quetel, Anne Tallet, et al.. (2016). Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2 , in Malignant Pleural Mesothelioma. Clinical Cancer Research. 23(12). 3191–3202. 60 indexed citations

13.

Prunier, Chloé, Véronique Josserand, Julien Vollaire, et al.. (2016). LIM Kinase Inhibitor Pyr1 Reduces the Growth and Metastatic Load of Breast Cancers. Cancer Research. 76(12). 3541–3552. 27 indexed citations

14.

Samuels, Sanne, Balázs Bálint, Heiko von der Leyen, et al.. (2016). Precision medicine in cancer: challenges and recommendations from an EU-funded cervical cancer biobanking study. British Journal of Cancer. 115(12). 1575–1583. 6 indexed citations

15.

Akbani, Rehan, Karl‐Friedrich Becker, Neil O. Carragher, et al.. (2014). Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational, and Basic Research: A Workshop Report. Molecular & Cellular Proteomics. 13(7). 1625–1643. 128 indexed citations

16.

Broutin, Sophie, Frédéric Commo, Leanne de Koning, et al.. (2013). Changes in Signaling Pathways Induced by Vandetanib in a Human Medullary Thyroid Carcinoma Model, as Analyzed by Reverse Phase Protein Array. Thyroid. 24(1). 43–51. 5 indexed citations

17.

Maire, Virginie, Céline Baldeyron, Marion Richardson, et al.. (2013). TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer. PLoS ONE. 8(5). e63712–e63712. 119 indexed citations

18.

Jacobs, Frank, Leanne de Koning, Linh‐Chi Bui, et al.. (2013). Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1832(6). 718–728. 13 indexed citations

19.

Quanz, Maria, Aurélie Herbette, Leanne de Koning, et al.. (2012). Heat Shock Protein 90α (Hsp90α) Is Phosphorylated in Response to DNA Damage and Accumulates in Repair Foci. Journal of Biological Chemistry. 287(12). 8803–8815. 76 indexed citations

20.

Corpet, Armelle, Leanne de Koning, Joern Toedling, et al.. (2010). Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. The EMBO Journal. 30(3). 480–493. 131 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact